Mendus AB (publ) (IMMU.ST)
SEK 8.51
(-1.06%)
SEK 8.51
(-1.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 24.48 Million SEK | -68.67% |
| 2022 | 78.16 Million SEK | 111.39% |
| 2021 | 36.97 Million SEK | 5.51% |
| 2020 | 35.04 Million SEK | 4022.82% |
| 2019 | 850 Thousand SEK | 0.0% |
| 2018 | 850 Thousand SEK | 0.0% |
| 2017 | 850 Thousand SEK | 0.0% |
| 2016 | 850 Thousand SEK | 0.0% |
| 2015 | 850 Thousand SEK | 0.0% |
| 2014 | 850 Thousand SEK | 0.0% |
| 2013 | 850 Thousand SEK | 0.0% |
| 2012 | 850 Thousand SEK | 0.0% |
| 2011 | 850 Thousand SEK | 0.0% |
| 2010 | 850 Thousand SEK | 0.0% |
| 2009 | 850 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 25.06 Million SEK | 2.35% |
| 2024 Q2 | 23.77 Million SEK | -5.16% |
| 2023 Q3 | 25.41 Million SEK | -73.09% |
| 2023 FY | 24.48 Million SEK | -68.67% |
| 2023 Q1 | 81.32 Million SEK | 4.05% |
| 2023 Q4 | 24.48 Million SEK | -3.66% |
| 2023 Q2 | 94.47 Million SEK | 16.16% |
| 2022 Q2 | 26.17 Million SEK | 1.35% |
| 2022 Q3 | 26.48 Million SEK | 1.18% |
| 2022 Q4 | 78.16 Million SEK | 195.11% |
| 2022 FY | 78.16 Million SEK | 111.39% |
| 2022 Q1 | 25.82 Million SEK | -30.15% |
| 2021 Q4 | 36.97 Million SEK | 6798.32% |
| 2021 Q1 | 987 Thousand SEK | -97.18% |
| 2021 FY | 36.97 Million SEK | 5.51% |
| 2021 Q2 | 755 Thousand SEK | -23.51% |
| 2021 Q3 | 536 Thousand SEK | -29.01% |
| 2020 Q2 | 850 Thousand SEK | 0.0% |
| 2020 Q1 | 850 Thousand SEK | 0.0% |
| 2020 FY | 35.04 Million SEK | 4022.82% |
| 2020 Q3 | 850 Thousand SEK | 0.0% |
| 2020 Q4 | 35.04 Million SEK | 4022.82% |
| 2019 Q4 | 850 Thousand SEK | 0.0% |
| 2019 FY | 850 Thousand SEK | 0.0% |
| 2019 Q2 | 850 Thousand SEK | 0.0% |
| 2019 Q3 | 850 Thousand SEK | 0.0% |
| 2019 Q1 | 850 Thousand SEK | 0.0% |
| 2018 Q3 | 850 Thousand SEK | 0.0% |
| 2018 Q2 | 850 Thousand SEK | 0.0% |
| 2018 Q1 | 850 Thousand SEK | 0.0% |
| 2018 FY | 850 Thousand SEK | 0.0% |
| 2018 Q4 | 850 Thousand SEK | 0.0% |
| 2017 Q4 | 850 Thousand SEK | 0.0% |
| 2017 Q3 | 850 Thousand SEK | 0.0% |
| 2017 Q2 | 850 Thousand SEK | 0.0% |
| 2017 Q1 | 850 Thousand SEK | 0.0% |
| 2017 FY | 850 Thousand SEK | 0.0% |
| 2016 Q1 | 850 Thousand SEK | 0.0% |
| 2016 Q3 | 850 Thousand SEK | 0.0% |
| 2016 Q4 | 850 Thousand SEK | 0.0% |
| 2016 Q2 | 850 Thousand SEK | 0.0% |
| 2016 FY | 850 Thousand SEK | 0.0% |
| 2015 FY | 850 Thousand SEK | 0.0% |
| 2015 Q4 | 850 Thousand SEK | 0.0% |
| 2015 Q1 | 850 Thousand SEK | 0.0% |
| 2015 Q3 | - SEK | -100.0% |
| 2015 Q2 | 850 Thousand SEK | 0.0% |
| 2014 Q4 | 850 Thousand SEK | 0.0% |
| 2014 FY | 850 Thousand SEK | 0.0% |
| 2014 Q3 | 850 Thousand SEK | 0.0% |
| 2014 Q2 | 850 Thousand SEK | 0.0% |
| 2014 Q1 | 850 Thousand SEK | 0.0% |
| 2013 Q3 | - SEK | -100.0% |
| 2013 Q4 | 850 Thousand SEK | 0.0% |
| 2013 Q2 | 850 Thousand SEK | 0.0% |
| 2013 FY | 850 Thousand SEK | 0.0% |
| 2012 Q3 | 850 Thousand SEK | 0.0% |
| 2012 FY | 850 Thousand SEK | 0.0% |
| 2012 Q4 | 850 Thousand SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | 850 Thousand SEK | 0.0% |
| 2011 FY | 850 Thousand SEK | 0.0% |
| 2010 FY | 850 Thousand SEK | 0.0% |
| 2009 FY | 850 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -52.128% |
| Ziccum AB (publ) | 857 Thousand SEK | -2757.41% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -391.826% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 79.32 Million SEK | 69.128% |
| Intervacc AB (publ) | 181 Thousand SEK | -13429.282% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -18.81% |
| Active Biotech AB (publ) | 3 Million SEK | -716.267% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 59.391% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -389.76% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 65.707% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -212.826% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -5675.472% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 77.451% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -697.655% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -849.147% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -2348.8% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 97.499% |
| Camurus AB (publ) | 24.5 Million SEK | 0.078% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 11.166% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 97.175% |
| Cyxone AB (publ) | 858 Thousand SEK | -2754.079% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -1331.21% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 33.471% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -3576.877% |
| SynAct Pharma AB | 637 Thousand SEK | -3744.27% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -2780.941% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -1290.574% |
| BioInvent International AB (publ) | 23.24 Million SEK | -5.352% |
| Alzinova AB (publ) | 800 Thousand SEK | -2961.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 77.004% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -3067.589% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 73.013% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 20.162% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 89.421% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -2208.011% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |